| Literature DB >> 30342247 |
Stefanie Hering1, Brigitta Loretz2, Thomas Friedli3, Claus-Michael Lehr4, Frank Stieneker5.
Abstract
The pharmaceutical industry invests enormous amounts of resources (>€1 billion and >10years) in the development of new products. External factors such as intensifying foreign competition and greater regulatory demands can negatively affect the profit margin, whereas the R&D productivity diminishes. To stay competitive and to maintain high R&D capabilities for developing new medicinal products, companies must make smart investment decisions to maximize their return on investment. Consequently, the entire lifecycle of a medicinal product must be effectively managed to ensure a sustained development through commercialization. This review critically assesses the current situation and the associated management strategies throughout the lifecycle of a medicinal product.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30342247 DOI: 10.1016/j.drudis.2018.10.008
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851